Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)

v3.20.1
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Net sales $ 194,680 $ 184,861 $ 562,857 $ 522,341
Cost of sales 64,617 60,251 192,977 177,110
Gross margin 130,063 124,610 369,880 345,231
Operating expenses:        
Selling, general and administrative 66,318 64,968 203,358 195,622
Research and development 15,954 15,552 48,413 46,154
Total operating expenses 82,272 80,520 251,771 241,776
Operating income 47,791 44,090 118,109 103,455
Other (expense) income (970) 5,787 96,843 (14,226)
Earnings before income taxes 46,821 49,877 214,952 89,229
Income taxes 10,389 5,223 44,501 9,617
Net earnings 36,432 44,654 170,451 79,612
Other comprehensive (loss) income:        
Foreign currency translation adjustments (19,403) 5,232 (15,138) (4,368)
Derivative instruments - cash flow hedges (5,702) (1,854) (4,798) (5,769)
Other comprehensive (loss) income (25,105) 3,378 (19,936) (10,137)
Comprehensive income $ 11,327 $ 48,032 $ 150,515 $ 69,475
Earnings per share:        
Basic (in dollars per share) $ 0.95 $ 1.18 $ 4.46 $ 2.11
Diluted (in dollars per share) $ 0.92 $ 1.15 $ 4.33 $ 2.05
Weighted average common shares outstanding:        
Basic (in shares) 38,303 37,772 38,167 37,745
Diluted (in shares) 39,435 38,861 39,354 38,813